Video

Dr. Rai on the Treatment Paradigm for CLL

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the change in the treatment paradigm for chronic lymphocytic leukemia (CLL).

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the change in the treatment paradigm for chronic lymphocytic leukemia (CLL).

According to Rai, the treatment paradigm is changing, contrary to the enthusiasm and excitement when new drugs were approved years ago. These treatments are effective but are not cures.

There is a learning curve as to how to best use these new drugs and whether they can be combined to have an additive and synergistic benefit for the patient, explains Rai.

Related Videos
Dr Sullivan on RP1 Plus Nivolumab in Anti–PD-1–Refractory Melanoma
Neeta Somaiah, MD
Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center